REDX Pharma (LON:REDX) new management team is continuing to focus its financial resources on progressing lead candidates in oncology and fibrotic disease into the clinic. An extensive internal review, led
Alliance Pharma (LON:APH) is a profitable, cash-generative, specialty pharma business. The proportion of sales generated from higher margin international star brands is rising rapidly, and will be boosted by the
International Lithium Corp (TSX:ILC) turnaround is continuing under stewardship of the new Chairman/CEO. Restructuring the Canadian assets shifts the focus towards the Raleigh Lake deposit, which has geological similarities with
Warpaint London Plc (LON:W7L) has released a trading update for the year ending 31 December 2018. The company has prudently signalled that group sales for FY2018 are likely to be
ValiRx Plc (LON:VAL) is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment of cancer. The company’s two leading assets are in clinical trials: VAL201 (Phase
Primary Health Properties (LON:PHP) dividend growth is set to accelerate. In addition, we see a number of drivers to NAV growth. PHP invests in Government-income-backed, long leases. Two years ago,
SatoshiPay is a developer of micropayment solutions for the digital economy. Its blockchain-based platform facilitates payments of small, even fractional, sums for online content and services. This delivers a much-needed
The 4 October results confirmed steady growth, controlled risk and delivery in line with expectations. Double-digit underlying revenue and earnings growth was generated from stable customer numbers, and achieved more
Palace Capital (LON:PCA) has almost doubled NAV since the initial investment in October 2013. Good income generation is evidenced by the EPRA EPS and the DPS track record, whilst undertaking
Diurnal Group (LON:DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead products target rare conditions where medical needs are currently unmet, with
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
